dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Subbiah, Vivek |
dc.contributor.author | Kreitman, Robert |
dc.contributor.author | Wainberg, Zev A. |
dc.contributor.author | Gazzah, A. |
dc.contributor.author | Lassen, Ulrik |
dc.contributor.author | Stein, Alexander |
dc.contributor.author | Elez, Elena |
dc.date.accessioned | 2023-07-05T07:57:22Z |
dc.date.available | 2023-07-05T07:57:22Z |
dc.date.issued | 2023-05 |
dc.identifier.citation | Subbiah V, Kreitman RJ, Wainberg ZA, Gazzah A, Lassen U, Stein A, et al. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat Med. 2023 May;29:1103–12. |
dc.identifier.issn | 1546-170X |
dc.identifier.uri | https://hdl.handle.net/11351/9967 |
dc.description | Recerca de resultats; Disseny d'assaig clínic |
dc.language.iso | eng |
dc.publisher | Nature Portfolio |
dc.relation.ispartofseries | Nature Medicine;29 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Càncer - Tractament |
dc.subject | Quimioteràpia combinada |
dc.subject | Anomalies cromosòmiques |
dc.subject.mesh | Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.subject.mesh | Mutation |
dc.title | Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1038/s41591-023-02321-8 |
dc.subject.decs | neoplasias |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.subject.decs | mutación |
dc.relation.publishversion | https://doi.org/10.1038/s41591-023-02321-8 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Subbiah V] Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. [Kreitman RJ] Laboratory of Molecular Biology, National Institutes of Health, Bethesda, MD, USA. [Wainberg ZA] Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. [Gazzah A] Drug Development Department (DITEP), Gustave Roussy Cancer Institute, Villejuif, France. [Lassen U] Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. [Stein A] Department of Internal Medicine II (Oncology Center), University Medical Center Hamburg-Eppendorf, Hamburg, Germany. [Elez Fernandez E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB-Quiron, UVic-UCC, Barcelona, Spain |
dc.identifier.pmid | 37059834 |
dc.identifier.wos | 000974906900004 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |